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Abstract
Background: Cystic Fibrosis (CF) patients are vulnerable to airway colonization with Pseudomonas aeruginosa. In case
eradication fails after antibiotic treatment, patients become chronically colonized with P. aeruginosa, with recurrent
pulmonary exacerbation, for which patients typically are hospitalized for 2 weeks and receive intravenous antibiotic
treatment. Normally, improvement of the patients’ health is established.
Aim: Determination of the correspondence between patient improvement and changes of the P. aeruginosa and total
bacterial load in the sputum.
Methods: Eighteen CF patients with exacerbation were included for a total of 27 hospitalization episodes. At day 1, 8 and
15, inflammation and lung function parameters were determined, together with the P. aeruginosa load in the sputum using
culture, quantitative PCR (qPCR) and propidium monoazide qPCR.
Results: Patients improved during hospitalization (decrease in levels of C-reactive protein, white blood cell counts and
erythrocyte sedimentation rate, increase of FEV1), reaching normal values already after one week. Also the P. aeruginosa
load and the total bacterial load decreased during the first week of antibiotic treatment (p,0.05), except for patients with a
low lung function (FEV1#39.4%), for whom no significant decrease of P. aeruginosa was established. Comparison of culture-
based and propidium monoazide qPCR-based quantification of P. aeruginosa showed that at the end of the treatment on
average 62% of the P. aeruginosa cells are not cultivable, indicating that many cells are alive but dormant, or dead but still
structurally intact.
Conclusion: Improvement of the clinical status is accompanied with a decrease of the P. aeruginosa load, whereby both
occur mainly during the first week of antibiotic treatment. However, for patients with a low lung function, no decrease of
the P. aeruginosa load is observed. Comparison of detection techniques shows that a large amount of noncultivable or dead
bacteria are present in the samples.
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Introduction
In cystic fibrosis (CF), the CFTR protein, which is expressed in
epithelial cells, is not or only partially functional due to mutations
in the Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) gene. As a consequence, these patients are vulnerable to
pulmonary bacterial infections. Although a diverse set of bacterial
species can be found in the CF airways [1], 80% of the patients at
the age of 25–34 are colonized with Pseudomonas aeruginosa, which is
still the most frequently isolated pathogen in CF patients [1]. In
many CF centres, the patients immediately receive aggressive
antibiotic treatment aiming at early eradication in case of P.
aeruginosa isolation in respiratory samples [2–5]. However,
complete eradication is not always achieved and patients may
become colonized. Colonized patients often have recurrent
infectious pulmonary exacerbations which is associated with
bronchial damage, reduced lung function, a faster decline in lung
function and a decreased median survival time [6–10]. The cause
for the increased frequency of these pulmonary exacerbations
remains poorly understood. It has been shown that the increased
frequency is at least partially correlated with oestrogens, the use of
inhaled steroids, lower FEV1 and/or a high frequency of previous
exacerbations [11,12]. At the Ghent University Hospital, patients
with an exacerbation are hospitalized for a period of 2 weeks and
receive intravenous antibiotics (aminoglycoside and beta-lactam).
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Although in general, CF patients improve during this hospital-
ization period, the reason for the improvement is still not well
explored. In this study, we investigated whether this improvement
can be correlated with a change in P. aeruginosa density and/or a
change of the total bacterial density in the sputum.
Materials and Methods
Patients and sampling
This study was approved by the ethical committee of Ghent
University Hospital (B67020109390). Written informed consent
was obtained from all the patients .18 years, or from the parents
and children older than 12 years.
All 18 patients that participated in the study were chronically
colonized with P. aeruginosa (according to the European Consensus
Criteria [2]). Clinical data and the antibiotic regime for each
patient are shown in Table 1. Sputum and blood samples were
collected at day 1 (prior to the start of the antibiotic treatment on
the same day), day 8 and day 15 of treatment for a total of 27
hospitalization periods, and inflammation parameters (C-reactive
protein (CRP), white blood cells (WBC), erythrocyte sedimentation
rate (ESR) and lung function (FEV1 and FVC) were determined.
Sample processing
Sputum samples were homogenized with Sputasol (Oxoid Ltd.,
Basingstoke, UK) (1:1, vol/vol, 1 h incubation at 37uC). Samples
were processed immediately after arrival at the lab, within 4 hours
of sample collection.
Microbiological culture
Homogenized sputum samples were diluted serially tenfold in
physiological saline. Twenty five ml of each dilution was inoculated
in triplicate on cetrimide agar plates. The P. aeruginosa load was
determined after 72 h of incubation at 37uC in ambient
atmosphere.
Propidium monoazide based inactivation of DNA from
dead cells
In order to inhibit the amplification of the DNA derived from
dead bacteria in the respiratory samples, the samples were treated
with propidium monoazide (PMA) [13,14]. In order to improve
the PMA cross-linking efficacy, the homogenized sputum sample
was split in four parts of each 200 ml and washed 3 times
(centrifugation for 5 min at 5000 g followed by resuspension of the
pellet in saline). After the final washing step, the 4 washed aliquots
were transferred to a 24-well plate and 10 ml 1 mM PMA (final
concentration: 50 mM) (Biotium, Hayward, CA) was added to two
190 ml sample aliquots (for PMA-qPCR) and 10 ml saline was
added to the other two 190 ml sample aliquots. After 30 min
incubation in the dark on a shaker, the samples were exposed to a
500 W halogen light source for 10 min at a distance of 20 cm.
During exposure, the 24-well plate was kept on ice to avoid
overheating of the samples.
DNA extraction
DNA extraction from the sputum samples was performed as
described previously [15,16]. Briefly, the sputum aliquots,
Table 1. Overview of the clinical background of the patients and the antibiotic treatment received during hospitalization.
Patient Gender Age CFTR Genotype # Episodes Antibiotic treatment
a
Macrolide TOBb COLb MPMb TAZb CAZb
1 M 26 DF508/DF508 1 Yes Yes ? ? Yes ?
2 V 20 DF508/DF508 3 Yes Yes (2, 3)c Yes (1, 2, 3) Yes (1, 2, 3) No No
3 M 24 DF508/DF508 2 Yes Yes (1, 2) No No Yes (1) Yes (2)
4 M 23 DF508/1717–1G-A 1 Yes Yes No No Yes No
5 M 14 DF508/DF508 2 Yes Yes (1, 2) No No Yes (1, 2) No
6 V 28 DF508/DF508 1 Yes Yes No No No Yes
7 M 14 DF508/G502X 2 Yes Yes (1, 2) No No Yes (2) Yes (1)
8 V 31 DF508/DF508 3 Yes Yes (1, 2, 3) Yes (1, 2, 3) No Yes (3) Yes (1, 2)
9 V 28 DF508/DF508 2 Yes Yes (2) No No Yes (2) Yes (1)
10 M 16 DF508/DF508 1 Yes Yes (1) No No No Yes (1)
11 M 30 DF508/DF508 2 Yes Yes (1, 2) No Yes (1, 2)e Yes (1)e No
12 V 18 DF508/L927P 1 Yes Yes No No No Yes
13 V 25 DF508/DF508 1 No Yesd Yesd No Yes No
14 M 29 DF508/N1303K 1 Yes No Yes No Yes No
15 M 34 DF508/S1251N 1 Yes No No No Yesd No
16 V 19 DF508/DF508 1 No Yes No No Yes No
17 V 44 DF508/DF508 1 Yes Yes No No Yes No
18 V 22 DF508/DF508 1 Yes Yes No No Yes No
Legend:
a: Antibiotic during hospitalization (except for the macrolide treatment).
b: TOB: tobramycin, COL: colimycine, MPM: meropenem, TAZ: tazocin, CAZ: ceftazidim.
c: Numbers between brackets: episode numbers during which the antibiotic was administered.
d: TOB was replaced by COL after one week of treatment.
e: During the first episode, TAZ was replaced by MPM after one week of treatment.
doi:10.1371/journal.pone.0079010.t001
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pretreated or not with 1 mM PMA as described above, were pre-
incubated during 1 h at 55uC with 200 ml proteinase K buffer
(1 mg/ml proteinase K, 0.5% SDS, 20 mM Tris-HCl, pH 8.3),
after which the DNA was extracted using the bioMe´rieux
easyMAG Nuclisens extractor (bioMe´rieux, Marcy-l9E´toile,
France).
Quantitative PCR
Quantitative PCR (qPCR) was performed as described previ-
ously [16]. All qPCR formats were carried out on the Light-
Cycler480 (Roche, Basel, Switzerland), using the LightCycler480
SYBR Green kit (Roche)(for quantification of 16S rDNA) or the
LightCycler480 Probes Master kit (for P. aeruginosa). Primers and
probes used in this study are listed in Table 2. The 16S rDNA
SYBR Green kit contained 5 ml SYBR Green Master Mix,
0.3 mM of each primer and 2 ml of DNA-extract. The final
reaction volume was made up to 10 ml by adding HPLC water.
For the P. aeruginosa hydrolysis probe assay, the reaction mixture
contained 5 ml Probes Master kit, 0.5 mM of each primer, 0.1 mM
of hydrolysis probe and 2.5 ml of DNA-extract, and the final
reaction volume was made up to 10 ml by adding HPLC water. A
standard tenfold dilution series was prepared by DNA-extraction
from a dense suspension of log phase P. aeruginosa strain PA14. The
P. aeruginosa DNA concentration was measured using the
Nanodrop D1000, and the number of P. aeruginosa cells (chromo-
somes) originally present was calculated. This standard dilution
series was used in the qPCR to construct a standard curve, which
enabled to relate the number of cells to Cq-values, and to calculate
the number of P. aeruginosa cells present in the samples.
Statistical analysis
Statistical analysis was performed using the IBM SPSS Statistics
20 software package. Paired non-parametric tests were performed
using the Wilcoxon test. P-values below 0.05 were considered as
statistically significant. The statistical correlation between different
parameters was assessed by means of the Spearman’s correlation
test.
Results
During 16 months, 18 patients (nine male, median age:
24.5 years) were included for a total of 27 hospitalization episodes
(Table 1). For eleven patients, there was only one hospitalization
episode, while five patients had two hospitalization episodes and
two patients had three. In case of multiple hospitalization episodes,
the median time interval between these episodes was 6 months.
Parameters of clinical improvement
Overall, there was a statistically significant improvement of all
the parameters during the full hospitalization period (Table 3). For
all parameters, the major improvement occurred during the
first week of treatment (statistically significant for CRP decrease
(p,0.001), WBC decrease (p = 0.007), FEV1 increase (p = 0.001)
and FVC increase (p = 0.001)) and CRP, ESR and WBC values
approached normal values. During the second week, there were
no significant changes in any of these parameters. Considering the
total treatment period, all parameters significantly improved.
Total bacterial load and P. aeruginosa load
The change in P. aeruginosa sputum density during the treatment
period was determined by three methods, i.e. i) quantitative
culture of the bacteria on cetrimide agar, selective for P. aeruginosa,
ii) propidium-monoazide qPCR (PMA-qPCR) and iii) qPCR, both
specific for P. aeruginosa. Since, theoretically, PMA-qPCR only
amplifies DNA of living cells (cultivable and non-cultivable), this
approach is considered to provide the most relevant bacterial load
estimates in this study, because culture does not detect the
dormant cells and qPCR also quantifies DNA from killed cells.
The PMA-qPCR median value on day 1 was 4.156107 cells/ml,
whereas it was 1.086107 cells/ml on day 8 and 5.376106 cel-ls/
ml on day 15 (Figure 1). For PMA-qPCR and for qPCR, the
decrease of P. aeruginosa was only statistically significant during the
first week of treatment (PMA-qPCR p=0.002, qPCR p=0.001)
and for the total treatment period (PMA-qPCR p=0.006, qPCR
p=0.012). According to culture results, there was a statistically
significant decrease during the first week of treatment (day 1–
day 8) (p = 0.03). However, during the second week of treatment
(day 8– day 15) there was an increase of the amount of P. aeruginosa
cells detected by culture (p = 0.046). Still, when considering the
total treatment period (day 1– day 15), the overall decrease was
significant (p = 0.037).
In this study, the values obtained with qPCR and PMA-qPCR
are on average 0.5 log10 higher than those obtained by culture
(culture vs PMA-qPCR p=0.022, culture vs qPCR p=0.008)
(Figure 1), indicating that a significant part of the P. aeruginosa cells
Table 2. Primers used in this study.
Target Primers/Probes Sequence (59R39) Annealing Temp (uC) Reference
Universal 16S rDNA abNOT (forward) AGTTTGATCCTGGCTCAG 50 [37]
Gamma (reversed) ACTGCTGCCTCCCGTAGGAG 50
P. aeruginosa - oprL Forward ACC CGA ACG CAG GCT ATG 55 [15,16]
Reversed CAG GTC GGA GCT GTC GTA CTC 55
Hydrolysis probe 6FAM-AGAAGGTGGTGATCGCACGCAGA-BBQ
doi:10.1371/journal.pone.0079010.t002
Table 3. Median values (ranges) for 27 episodes of
hospitalization (18 patients) for the clinical parameters
obtained at days 1, 8 and 15 of hospitalization.
Parameters
Median
Day 1
Median
Day 8
Median
Day 15
CRP (mg/L) 22 (1–123) 4* (1–4.7) 4* (1–3.1)
WBC
(103 cells/ml)
11.61 (6.12–32.83) 9.42*
(4.93–14.80)
9.41* (4.02–14.45)
ESR (mm/h) 27 (4–62) 23 (2–70) 20* (2–62)
FVC (%) 70 (29–99) 77* (39–117) 80* (37–113)
FEV1 (%) 44 (0.16–0.82) 53* (0.19–1.03) 55* (0.19–1.00)
Significant change in comparison with day 1, p,0.05 (Wilcoxon).
doi:10.1371/journal.pone.0079010.t003
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in the sputum is alive but not cultivable. However, it should be
noted that part of the cells may be dead but still structurally intact,
with as a result that PMA can not invade the cells and as such not
inhibit the amplification of DNA of dead cells, leading to an
underestimation of the number of dead cells. Moreover, PMA-
qPCR values were on average 0.1 log10 lower than those obtained
with qPCR, suggesting that part of the bacterial cells were dead/
killed.
Also the total bacterial load (by means of a general 16S rRNA
gene qPCR) was determined on the PMA-treated samples.
Although, there was no significant decrease over the one week
intervals (day 1– day 8 and day 8– day 15), the decrease over
15 days was significant (p = 0.048).
Correlation between parameters of clinical improvement
and bacterial load
During the first week of treatment, not only the parameters
WBC, ESR, CRP and FEV1 (Table 3), but also the P. aeruginosa
density, as determined by means of culture, PMA-qPCR and
qPCR, decreased significantly (all p,0.05) (Figure 1). During the
second week of treatment, no statistically significant improvements
of the clinical parameters were observed as well as no statistically
significant decreases of the P. aeruginosa load. Grouping the patients
based on their FEV1 values at the start of the hospitalization
episode (first quartile: 4 patients (for 7 episodes) with
FEV1#39.4%; fourth quartile: 6 patients (for 7 episodes) with
FEV1$73.0%) shows that for the 4
th quartile (FEV1$73.0%), i.e.
the patients with the best lung function, the decrease of P. aeruginosa
load during the treatment is significant for PMA-qPCR (p= 0.011)
and qPCR (p= 0.026), while no statistical significant decrease is
established for the patients with a FEV1#39.4% (PMA-qPCR
p=0.128, qPCR p=0.209) (Table 4).
Uncultivable cells
As indicated in Figure 1, the P. aeruginosa values obtained by
PMA-qPCR (estimating the load of all living cells) are 0.5 log10
higher compared to those obtained by culture (estimating the load
of the cultivable cell fraction), indicating that a part of the P.
aeruginosa bacteria is not cultivable. Considering all episodes,
41.7% of all living P. aeruginosa bacterial cells are not cultivable at
day 1, 90.2% not at day 8 and 62.6% not at day 15 (Table 5).
When comparing the patients with poor lung function (Q1, FEV1
value #39.4%) with those with a high FEV1 value (Q4, $73.0%),
the former have already a high amount of not cultivable cells at the
start of the treatment (5.866107/ml, 77.3%), while for the patients
with good lung function only 49.1% (2.516107/ml) of the cells are
not cultivable. At the end of the treatment both groups have a high
proportion of dormant cells (FEV1 Q1: 93.1% and FEV1 Q4:
100%). However, the absolute values are 100-fold lower for the
patients with good lung function (5.836104/ml) compared to those
with poor lung function (8.326106/ml) (Table 5).
Discussion
Intravenous antibiotic treatment improves clinical
parameters
It is common practice to hospitalize CF patients with a
pulmonary exacerbation for a 14-day treatment period [17–22].
In agreement with other studies [17–22], we observed an
improvement of the clinical parameters of the treated patients
over a 14-day treatment period. In some papers, also a 10-day
period of intravenous treatment is found to be sufficient to
improve the clinical parameters [23–27]. Indeed, our data indicate
that inflammation parameters (CRP, WBC, ESR) and lung
function (measured as FEV1 and FVC) significantly improve
during the first week, with no further significant improvement
during the second week. It should be noted that after one week the
values had already returned to normal, such that further
improvement during the second week is not expected. As stated
by Plummer and Wildman [28], a shorter treatment may have
several benefits, such as improvement of the life quality of the
patient and a lower hospitalization cost, but they also remark that
the outcome on the long term of such short treatment periods is
unknown and that, for instance, the relapse time to the next
exacerbation might be shorter.
Intravenous antibiotic treatment decreases total bacterial
load and P. aeruginosa load
In accordance with the change of the clinical parameters and in
accordance with the culture-based study of Regelmann et al. [18],
the major decrease of total bacterial load and of P. aeruginosa load
occurred during the first week of treatment.
The number of bacteria determined by means of PMA-qPCR
minus the number of cultivable cells allows us to estimate the
number of dormant, non-cultivable cells. The load as determined
by microbiological culture was on average 0.5 log10 lower than the
Figure 1. Median density (for 27 samples from 18 patients) of P. aeruginosa cells/ml sputum at hospitalization days 1, 8 and 15, as
determined by the three quantification techniques, i.e. culture, qPCR and PMA-qPCR. * = statistically significant (p,0.05).
doi:10.1371/journal.pone.0079010.g001
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load as determined by PMA-qPCR, indicating a high amount of
not cultivable bacteria. This high number of dormant cells might
be explained by the availability of nutrients and oxygen which
decrease with the depth in the biofilm [29,30] and which lead to a
mixture of metabolically active (dividing) and metabolically
inactive (dormant, non-dividing) bacteria. Is has been shown that
these dormant cells are less susceptible to antibiotics and are
difficult to detect by culture [30–32]. Taking all 27 episodes of 18
patients in consideration, we notice that after one week of
treatment 90% of all P. aeruginosa bacteria were dormant, while
at the start of the treatment only 41.7% of all P. aeruginosa bacteria
were dormant. Although at day 15 the absolute amount of
dormant cells further decreased, relatively, there were only 62.6%
dormant cells. However, it should be noted that PMA can not
invade dead cells which are structurally still intact, so this is still an
estimation.
Taking the two outer patient quartile groups in consideration,
i.e. the patients with the worst and the best FEV1 values, the
proportion of dormant cells even increase after 15 days of
treatment to 93.1% and 100%, respectively. The difference
between the relative amounts at day 15 for all patients and for
the two FEV1 outer groups might be explained by the large spread
of quantities in bacterial load when all patients are included.
However, these findings illustrate that preferentially the
metabolic active cells are killed during antibiotic treatment and
are indicative for the need of alternative treatments targeting the
dormant bacteria.
Because the load of PMA-qPCR was on average 0.1 log10 below
that of qPCR, it can be concluded that there is a significant
amount of DNA derived from dead cells present in the sputum, i.e.
23% of total P. aeruginosa DNA at day 0, 70% at day 8 and 42% at
day 15. In agreement with the suggestion of Rogers and colleagues
[33], this comparison of techniques shows that the treatment
success should be determined by means of PMA-qPCR, since all
viable cells are quantified (unlike culture, which does not quantify
dormant cells) and since only viable cells are quantified (unlike
qPCR, which also quantifies DNA from dead cells).
Correlation between the improvement of clinical
parameters and the decrease of bacterial load
In our study, we observed that clinical improvements and the
decreases of P. aeruginosa and of total bacterial load are mainly
established during the first week of antibiotic treatment.
Stressmann and colleagues [34] monitored the total number of
bacteria and of P. aeruginosa in sputum samples of 12 adult CF
patients, 21, 14, 7 and 0 days prior to a pulmonary exacerbation.
Interestingly, they did not find significant changes in the bacterial
load (total and/or P. aeruginosa) in the period prior to pulmonary
exacerbation, suggesting that these exacerbations do not result
from an increased bacterial density.
In some studies, the role of other bacterial species and the
composition of the microbiome prior to and during pulmonary
exacerbations have been identified. Using culture based tech-
niques, Worlitzsch et al. [35] investigated the role of obligate
anaerobes during pulmonary exacerbation and found that the
number of obligate anaerobes was not reduced during intravenous
therapy directed against P. aeruginosa [35]. By means of
pyrosequencing, Fodor et al. [36] found that there is only a
minimal change in the overall microbial community structure
during antibiotic treatment. Moreover, they also found a similar
microbiome in patients when clinical stable and during an
Table 4. Median and range of P. aeruginosa loads (cfu/ml for culture, chromosomes/ml for qPCR) of the patients, grouped based
on the FEV1 values at the end of the treatment (Q1: FEV1#39.4%, Q4: FEV1$73.0%).
Quantification technique FEV1 quartile Day 1 Day 8 Day 15
Culture Q1 1.76107 1.86106 6.26105
6.36104–2.16108 5.86104–3.16107 0–1.46108
Q4 2.66107 1.06104 0
2.26105–8.46107 0–6.06106 0–5.06107
PMA-qPCR Q1 7.66107 1.36107 8.96106
1.66104–3.46108 0–5.86107 0–9.46107
Q4 5.16107 6.66104 a 5.86104 b
6.16104–1.76108 1.96104–1.76107 1.16104–3.66107
qPCR Q1 7.26107 3.06107 2.46107
1.56104–2.86108 0–8.36107 0–1.86108
Q4 6.66107 2.26105 a 9.96104 b
9.16104–1.76108 2.76104–4.56107 1.76104–5.86107
a: Statistical significant decrease of P. aeruginosa after the first week of treatment (p,0.05).
b: Statistical significant decrease of P. aeruginosa after two weeks of treatment (p,0.05).
doi:10.1371/journal.pone.0079010.t004
Table 5. Amount of dormant P. aeruginosa bacterial cells (/
ml) in the CF sputum, i.e. number of cells obtained by means
of PMA-qPCR minus the number of cells obtained by means of
culturing (mean values).
All episodes (27) FEV1 Q1 (7) FEV1 Q4 (7)
Day 1 1.936107 (41.7%) 5.866107 (77.3%) 2.516107 (49.1%)
Day 8 9.746106 (90.2%) 1.166107 (86.6%) 5.646104 (84.9%)
Day 15 3.366106 (62.6%) 8.326106 (93.1%) 5.836104 (100%)
The relative amount of dormant P. aeruginosa bacteria against all living P.
aeruginosa bacteria is indicated between brackets.
doi:10.1371/journal.pone.0079010.t005
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exacerbation, suggesting that the onset of exacerbations is not
correlated with a change in the airway microbiome [36].
A comparable study as ours was carried out by Regelmann et al.
[18]. They determined the P. aeruginosa and total bacterial density
in the sputum in an antibiotic treated group (n= 7) and in a
placebo group (n= 5) and measured the lung function improve-
ment of the patients in both groups (FVC, FEV1 and FEF25–75). In
their study, reduction of the P. aeruginosa density was quantitatively
correlated with the improvement of the above mentioned
parameters (ANOVA). Our data show that both the parameters
of clinical improvement and the P. aeruginosa load, the latter
determined by means of PMA-qPCR, improve significantly only
during the first week. It should be noticed that the parameters of
clinical improvement reach already normal values after one week
of treatment, such that further improvement during the second -
week is not possible. Interestingly, we found that for the 6 patients
(7 episodes) with a good lung function (FEV1.73.0%), a
significant decrease of the P. aeruginosa density, determined by
means of PMA-qPCR could be obtained while this was not the
case for the 4 patients (7 episodes) with a poor lung function
(FEV1,39.4%). This defective clearance of P. aeruginosa in the
latter group may be due to enhanced intrinsic resistance of the P.
aeruginosa cells, but is probably better explained as being due to an
enhanced biofilm network in the airways which makes the bacteria
less reachable for the antibiotics in combination with the
deterioration of the lung tissue and the immune defense of the
patients.
In conclusion, we can state that the improvement of clinical
status is accompanied with the decrease of the P. aeruginosa load,
and that these decreases occur mainly during the first week of IV
antibiotic treatment. Our data also indicate that the antibiotic
treatment has a higher impact (regarding the decrease of the P.
aeruginosa load) in patients with a good lung function (.73.0%).
Finally, comparison of the quantitation of P. aeruginosa by means of
culture with quantitation by means of PMA-qPCR illustrates that
clearance of the dormant, non-cultivable bacteria present in the
sputum is difficult to achieve with the currently applied treatments.
To determine to what extent the decrease in bacterial load
could have been caused by the physiotherapy that normally
accompanies antibiotic treatment, we checked bacterial loads
before and after physiotherapy treatment in patients that received
only physiotherapy, but could not establish a diminishment of
bacterial concentrations (not sufficient patients for statistical
analysis, data not published). It can be assumed that physiotherapy
alone, and most certainly when combined with intravenous
antibiotics, decreases the sputum in the airways, but it seems
unlikely that physiotherapy alone influences the bacterial load, i.e.
the number of bacteria per volume of sputum, which is in
correspondence with our unpublished data.
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